![Agios Pharmaceuticals Inc.: Agios Reports Business Highlights and First Quarter 2023 Financial Results - Form 8-K - MoneyController (ID 1346441) Agios Pharmaceuticals Inc.: Agios Reports Business Highlights and First Quarter 2023 Financial Results - Form 8-K - MoneyController (ID 1346441)](https://www.moneycontroller.fr/upload/aziende/agios-pharmaceuticals-inc_20210426151617.png)
Agios Pharmaceuticals Inc.: Agios Reports Business Highlights and First Quarter 2023 Financial Results - Form 8-K - MoneyController (ID 1346441)
Agios Pharmaceuticals on LinkedIn: CohnReznick Announces the Winners of its Inaugural Gamechangers in ESG…
![Press release: For third year the Cooperation Between The Municipality of Agios Nikolaos and Costa Nostrum is Continuing | Costa Nostrum Press release: For third year the Cooperation Between The Municipality of Agios Nikolaos and Costa Nostrum is Continuing | Costa Nostrum](https://cdn.costanostrum.org/wp-content/uploads/elementor/thumbs/daean-costa-nostrum-38186-pnee2by5909y83mdxt6foinhh54s5utxhlo0f118g0.jpg)
Press release: For third year the Cooperation Between The Municipality of Agios Nikolaos and Costa Nostrum is Continuing | Costa Nostrum
![The completion of the Conservation of Agios Georgios church in the Karpas area | United Nations Development Programme The completion of the Conservation of Agios Georgios church in the Karpas area | United Nations Development Programme](https://www.undp.org/sites/g/files/zskgke326/files/2023-07/completion_agios_georgios_karpas_6.jpg)
The completion of the Conservation of Agios Georgios church in the Karpas area | United Nations Development Programme
![Agios on X: "We're proud to announce that data from the pivotal Phase 3 ACTIVATE study of PYRUKYND ® (mitapivat) were published on April 14, 2022 in the New England Journal of Agios on X: "We're proud to announce that data from the pivotal Phase 3 ACTIVATE study of PYRUKYND ® (mitapivat) were published on April 14, 2022 in the New England Journal of](https://pbs.twimg.com/ext_tw_video_thumb/1514587815912386562/pu/img/UpHI6lBJLZmyjpK6.jpg)
Agios on X: "We're proud to announce that data from the pivotal Phase 3 ACTIVATE study of PYRUKYND ® (mitapivat) were published on April 14, 2022 in the New England Journal of
![Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition | AGIO Stock News Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition | AGIO Stock News](https://static.stocktitan.net/company-logo/AGIO-tmb.webp)